Journal article
Activity of meropenem/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014–19)
Journal of antimicrobial chemotherapy, Vol.76(10), pp.2600-2605
09/15/2021
DOI: 10.1093/jac/dkab252
PMCID: PMC8446919
PMID: 34302173
Abstract
Objectives
Meropenem/vaborbactam has been approved in Europe for the treatment of hospital-acquired bacterial pneumonia, ventilator-associated pneumonia (VAP) and bacteraemia among other indications. Vaborbactam is an inhibitor of class A and C β-lactamases, including Klebsiella pneumoniae carbapenemase (KPC) enzymes, but not class B or D carbapenemases. We analysed the activity of meropenem/vaborbactam and comparators against 6846 Enterobacterales and 3567 Pseudomonas aeruginosa isolates from patients hospitalized with pneumonia (PHP), including VAP.
Methods
Isolates from PHP were consecutively collected during 2014–19 from 42 European hospitals located in 21 countries and susceptibility tested using the broth microdilution method. Carbapenem-resistant Enterobacterales (CRE) isolates were molecularly characterized to identify their carbapenem-resistance mechanisms. EUCAST (2020) interpretive criteria were used.
Results
The most common Gram-negative pathogens isolated from PHP were P. aeruginosa (n = 3567), K. pneumoniae (n = 1877) and Escherichia coli (n = 1646). Overall, 98.0% of Enterobacterales and 82.1% of P. aeruginosa were susceptible to meropenem/vaborbactam, with 99.8% of Enterobacterales and 89.7% of P. aeruginosa in Western Europe (WE) and 92.7% of Enterobacterales and 69.1% of P. aeruginosa in Eastern Europe (EE). CRE were more common in EE (15.1%) than WE (2.1%). KPC was the most common carbapenemase in WE, while OXA-48-like was the most common carbapenemase in EE. Meropenem/vaborbactam susceptibility was 63.0% for all CRE (92.2% in WE and 51.5% in EE). Meropenem/vaborbactam inhibited 99.1% of KPC-producing isolates and 40.5% of OXA-48-like-producing isolates.
Conclusions
These in vitro data demonstrate that meropenem/vaborbactam has potent activity against isolates from PHP, including isolates producing KPC, and may be a useful treatment option for PHP, including VAP.
Details
- Title: Subtitle
- Activity of meropenem/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014–19)
- Creators
- Dee Shortridge - JMI LaboratoriesCecilia Carvalhaes - JMI LaboratoriesLalitagauri Deshpande - JMI LaboratoriesMariana Castanheira - JMI Laboratories
- Resource Type
- Journal article
- Publication Details
- Journal of antimicrobial chemotherapy, Vol.76(10), pp.2600-2605
- Publisher
- Oxford University Press
- DOI
- 10.1093/jac/dkab252
- PMID
- 34302173
- PMCID
- PMC8446919
- ISSN
- 0305-7453
- eISSN
- 1460-2091
- Grant note
- name: A. MENARINI Industrie Farmaceutiche Riunite
- Language
- English
- Date published
- 09/15/2021
- Academic Unit
- Pathology
- Record Identifier
- 9984185177302771
Metrics
16 Record Views